P215 Description of baseline characteristics of pediatric allergic asthma patients including those initiated on omalizumab

In light of recent omalizumab approval for uncontrolled moderate-to-severe allergic asthma (AA) patients aged 6-11 years, baseline characteristics of this population were described from a real-world dataset.

http://ift.tt/2iFigBW